Parkinson-related genetics in patients treated with deep brain stimulation

Acta Neurologica Scandinavica

Volumn 123, Issue 3, 2011, Pages 201-206

  Johansen, K K ^a,b   Jorgensen J V ^b   White, L R ^a,b   Farrer, M J ^c   Aasly, J O ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c MAYO CLINIC   (United States)

Author keywords

GPi; LRRK2; P.G2019S; PINK1; PRKN; STN; VIM

Indexed keywords

ADULT; ARTICLE; BRAIN DEPTH STIMULATION; FEMALE; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; GLOBUS PALLIDUS; HUMAN; LRRK2 GENE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PINK1 GENE; PRKN GENE; SUBTHALAMIC NUCLEUS; THALAMUS VENTRAL NUCLEUS;

AGED; DEEP BRAIN STIMULATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; RETROSPECTIVE STUDIES;

EID: 79251515770     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01387.x     Document Type: Article

References (22)

1. Healy DG, Falchi M, O'Sullivan SS et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7:583-90.
2. Aasly JO, Toft M, Fernandez-Mata I et al. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol 2005;57:762-5.
3. Alcalay RN, Mejia-Santana H, Tang MX et al. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Arch Neurol 2009;66:1517-22.
4. Ahlskog JE. Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease. Parkinsonism Relat Disord 2009;15:721-7.
5. Ishihara-Paul L, Hulihan MM, Kachergus J et al. PINK1 mutations and parkinsonism. Neurology 2008;71:896-902.
6. Bonifati V, Rohe CF, Breedveld GJ et al. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 2005;65:87-95.
7. Krack P, Batir A, Van Blercom N et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003;349:1925-34.
8. Limousin P, Pollak P, Benazzouz A et al. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995;345:91-5.
9. Benabid AL, Pollak P, Gervason C et al. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 1991;337:403-6.
10. Hariz MI, Krack P, Alesch F et al. Multicentre European study of thalamic stimulation for parkinsonian tremor: a 6year follow-up. J Neurol Neurosurg Psychiatry 2008;79:694-9.
11. Moro E, Volkmann J, Konig IR et al. Bilateral subthalamic stimulation in Parkin and PINK1 parkinsonism. Neurology 2008;70:1186-91.
12. Romito LM, Contarino MF, Ghezzi D, Franzini A, Garavaglia B, Albanese A. High frequency stimulation of the subthalamic nucleus is efficacious in Parkin disease. J Neurol 2005;252:208-11.
13. Schupbach M, Lohmann E, Anheim M et al. Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations. Mov Disord 2007;22:119-22.
14. Capecci M, Passamonti L, Annesi F et al. Chronic bilateral subthalamic deep brain stimulation in a patient with homozygous deletion in the parkin gene. Mov Disord 2004;19:1450-2.
15. Bejjani BP, Dormont D, Pidoux B et al. Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance. J Neurosurg 2000;92:615-25.
16. Reichmann H, Herting B, Miller A, Sommer U. Switching and combining dopamine agonists. J Neural Transm 2003;110:1393-400.
17. Myhre R, Toft M, Kachergus J et al. Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population. Acta Neurol Scand 2008;118:320-7.
18. Haugarvoll K, Toft M, Skipper L et al. Fine-mapping and candidate gene investigation within the PARK10 locus. Eur J Hum Genet 2009;17:336-43.
19. Skipper L, Wilkes K, Toft M et al. Linkage disequilibrium and association of MAPT H1 in Parkinson disease. Am J Hum Genet 2004;75:669-77.
20. Toft M, Aasly J, Bisceglio G et al. Parkinsonism, FXTAS, and FMR1 premutations. Mov Disord 2005;20:230-3.
21. Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord 2005;20:342-4.
22. Jankovic J, Mcdermott M, Carter J et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990;40:1529-34.